TETRAHYDRO-ISOHUMULONE DERIVATIVES, METHODS OF MAKING AND USING
申请人:KINDEX PHARMACEUTICALS, INC.
公开号:US20150119461A1
公开(公告)日:2015-04-30
The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.
Tetrahydro-isohumulone derivatives, methods of making and using
申请人:KINDEX PHARMACEUTICALS, INC.
公开号:US10343977B2
公开(公告)日:2019-07-09
The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.
Cann, Martin R.; Davis, Anne-Marie; Shannon, Patrick V. R., Journal of the Chemical Society. Perkin transactions I, 1982, p. 375 - 384
作者:Cann, Martin R.、Davis, Anne-Marie、Shannon, Patrick V. R.
DOI:——
日期:——
Bondeel, Georges M. A.; Keukeleire, Denis De; Verzele, Maurice, Journal of the Chemical Society. Perkin transactions I, <hi>1987</hi>, p. 2715 - 2719
作者:Bondeel, Georges M. A.、Keukeleire, Denis De、Verzele, Maurice
DOI:——
日期:——
METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION
申请人:Carroll Brian J.
公开号:US20110257074A1
公开(公告)日:2011-10-20
Methods of purifying individual congeners of substituted cyclohexa-2,4-dienones, substituted cyclohexane-1,3,5-triones, substituted cyclopent-2-en-1-ones, and substituted 1,3-cyclopentadiones and compositions using the same are disclosed. The purification method includes the steps of: (a) selecting a congener to be isolated; (b) dissolving the mixture of congeners in a bi-phasic solvent system specific to the selected congener to be isolated, wherein said bi-phasic system has a partition coefficient from about 0.5 to 5.0; (c) subjecting the mixture dissolved in the bi-phasic solvent system to a counter current chromatography; and (d) isolating the selected congener in substantially pure form.